This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Nuvilex’s Diabetes Treatment Utilizing Implanted Encapsulated, Insulin-Producing Cells Potentially Eliminates Need For Diabetic Drugs

Nuvilex, Inc. (OTCQB: NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today provided additional details based on the Goldman Small Cap Research report issued February 29, 2012, that highlighted the company’s cell encapsulation technology and its benefits for treating chronic diseases such as diabetes. The Company’s technology involves encapsulating insulin-producing cells that respond to changes in glucose levels into the Cell-in-a-Box® platform. As a result, the treatment would potentially eliminate the need for diabetes patients to continually test their glucose levels and inject insulin.

The Goldman report cited the completed animal study wherein SG Austria successfully treated diabetes in an established, recognized animal model utilizing live encapsulated cells. In the study, the introduced cells responded to elevated blood sugar levels by producing insulin, thereby alleviating the symptoms of diabetes. Moreover, encapsulated cells remained viable and responsive for many months.

The report stated, “This data, as well as previously published results, demonstrate it is feasible to overcome the basis for diabetes by implanting encapsulated, insulin-producing cells. This should pave the way for future clinical trials of encapsulated cells as a means to continuously regulate blood glucose for months, eliminating the need for daily glucose assessment and insulin injections. Such treatment would present a more natural means of providing insulin to patients, mimicking the body's own insulin production and thereby maintaining healthy blood glucose levels.

“The long term effects of diabetes include kidney failure, blindness, heart disease, amputations, and stroke. The World Health Organization (WHO) reports  346 million people in the world have diabetes and 4 million deaths occur globally each year. In fact, more than $378 billion is spent annually on diabetes treatment with the number expected to rise to $490 billion by 2030.”

The report concluded that, “Although it is early in the development process, the prospects on the diabetes front could be huge for the Company.” Goldman set a current value of Nuvilex at $0.30 per share with a six month price target of $0.50 per share based on the cell encapsulation technology and the favorable clinical and pre-clinical trial results across multiple biotechnology fields.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,698.18 -77.94 -0.44%
S&P 500 2,059.69 -8.20 -0.40%
NASDAQ 4,880.2280 -20.6570 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs